Kathrin Klein

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11262365/publications.pdf

Version: 2024-02-01

79	7,864	71102	62596
papers	citations	41 h-index	80 g-index

81	81	81	7887
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Hepatic Expression of the Na+-Taurocholate Cotransporting Polypeptide Is Independent from Genetic Variation. International Journal of Molecular Sciences, 2022, 23, 7468.	4.1	6
2	Triâ€Allelic Haplotypes Determine and Differentiate Functionally Normal Allele CYP2D6*2 and Impaired Allele CYP2D6*41. Clinical Pharmacology and Therapeutics, 2021, 109, 1256-1264.	4.7	7
3	Characterization of cytochrome P450 (CYP) 2D6 drugs as substrates of human organic cation transporters and multidrug and toxin extrusion proteins. British Journal of Pharmacology, 2021, 178, 1459-1474.	5.4	7
4	PharmVar GeneFocus: CYP2B6. Clinical Pharmacology and Therapeutics, 2021, 110, 82-97.	4.7	108
5	Effects of a Common Eight Base Pairs Duplication at the Exon 7-Intron 7 Junction on Splicing, Expression, and Function of OCT1. Frontiers in Pharmacology, 2021, 12, 661480.	3.5	2
6	Differential effects on human cytochromes P450 by CRISPR/Cas9-induced genetic knockout of cytochrome P450 reductase and cytochrome b5 in HepaRG cells. Scientific Reports, 2021, 11, 1000.	3.3	6
7	Effects of Diminished NADPH:cytochrome P450 Reductase in Human Hepatocytes on Lipid and Bile Acid Homeostasis. Frontiers in Pharmacology, 2021, 12, 769703.	3.5	6
8	Copy number variation profiling in pharmacogenes using panel-based exome resequencing and correlation to human liver expression. Human Genetics, 2020, 139, 137-149.	3.8	9
9	MiR-155 and other microRNAs downregulate drug metabolizing cytochromes P450 in inflammation. Biochemical Pharmacology, 2020, 171, 113725.	4.4	32
10	Factors Affecting Interindividual Variability of Hepatic UGT2B17 Protein Expression Examined Using a Novel Specific Monoclonal Antibody. Drug Metabolism and Disposition, 2019, 47, 444-452.	3.3	8
11	A New Panel-Based Next-Generation Sequencing Method for ADME Genes Reveals Novel Associations of Common and Rare Variants With Expression in a Human Liver Cohort. Frontiers in Genetics, 2019, 10, 7.	2.3	37
12	Direct Quantification of Cytochromes P450 and Drug Transportersâ€"A Rapid, Targeted Mass Spectrometry-Based Immunoassay Panel for Tissues and Cell Culture Lysates. Drug Metabolism and Disposition, 2018, 46, 387-396.	3.3	32
13	Epigenetics and MicroRNAs in Pharmacogenetics. Advances in Pharmacology, 2018, 83, 33-64.	2.0	15
14	Methyleugenol DNA adducts in human liver are associated with SULT1A1 copy number variations and expression levels. Archives of Toxicology, 2017, 91, 3329-3339.	4.2	30
15	Membrane Associated Progesterone Receptors: Promiscuous Proteins with Pleiotropic Functions â€“ Focus on Interactions with Cytochromes P450. Frontiers in Pharmacology, 2017, 8, 159.	3.5	80
16	Effect of Genetic Variability in the CYP4F2, CYP4F11, and CYP4F12 Genes on Liver mRNA Levels and Warfarin Response. Frontiers in Pharmacology, 2017, 8, 323.	3.5	21
17	Peroxisome proliferator-activated receptor alpha, PPARÎ±, directly regulates transcription of cytochrome P450 CYP2C8. Frontiers in Pharmacology, 2015, 6, 261.	3.5	29
18	The truncated splice variant of peroxisome proliferator-activated receptor alpha, PPARÎ±-tr, autonomously regulates proliferative and pro-inflammatory genes. BMC Cancer, 2015, 15, 488.	2.6	31

#	Article	IF	Citations
19	Multiplexed Targeted Quantitative Proteomics Predicts Hepatic Glucuronidation Potential. Drug Metabolism and Disposition, 2015, 43, 1331-1335.	3.3	39
20	Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms. Archives of Toxicology, 2015, 89, 2089-2103.	4.2	86
21	Isoniazid Mediates the CYP2B6*6 Genotype-Dependent Interaction between Efavirenz and Antituberculosis Drug Therapy through Mechanism-Based Inactivation of CYP2A6. Antimicrobial Agents and Chemotherapy, 2014, 58, 4145-4152.	3.2	23
22	Targeting Nuclear Receptors with Lentivirus-Delivered Small RNAs in Primary Human Hepatocytes. Cellular Physiology and Biochemistry, 2014, 33, 2003-2013.	1.6	14
23	Novel CYP2B6 Enzyme Variants in a Rwandese Population: Functional Characterization and Assessment of In Silico Prediction Tools. Human Mutation, 2013, 34, 725-734.	2.5	28
24	Expression Variability of Absorption, Distribution, Metabolism, Excretionâ€“Related MicroRNAs in Human Liver: Influence of Nongenetic Factors and Association with Gene Expression. Drug Metabolism and Disposition, 2013, 41, 1752-1762.	3.3	108
25	ABCC11/MRP8 polymorphisms affect 5-fluorouracil-induced severe toxicity and hepatic expression. Pharmacogenomics, 2013, 14, 1433-1448.	1.3	21
26	TheCYP2B6*6Allele Significantly Alters theN-Demethylation of Ketamine Enantiomers In Vitro. Drug Metabolism and Disposition, 2013, 41, 1264-1272.	3.3	45
27	Pharmacogenomics of Cytochrome P450 3A4: Recent Progress Toward the â€œMissing Heritabilityâ€• Problem. Frontiers in Genetics, 2013, 4, 12.	2.3	181
28	Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Frontiers in Genetics, 2013, 4, 24.	2.3	270
29	Abundance of DNA adducts of methyleugenol, a rodent hepatocarcinogen, in human liver samples. Carcinogenesis, 2013, 34, 1025-1030.	2.8	50
30	Direct Transcriptional Regulation of Human Hepatic Cytochrome P450 3A4 (CYP3A4) by Peroxisome Proliferatorâ€“Activated Receptor Alpha (PPARÎ±). Molecular Pharmacology, 2013, 83, 709-718.	2.3	88
31	The Letrozole Phase 1 Metabolite Carbinol as a Novel Probe Drug for UGT2B7. Drug Metabolism and Disposition, 2013, 41, 1906-1913.	3.3	8
32	Functional polymorphisms of xenobiotics metabolizing enzymesâ€”a research topic. Frontiers in Genetics, 2013, 4, 79.	2.3	3
33	Bioactivation of chlorpyrifos by CYP2B6 variants. Xenobiotica, 2012, 42, 1255-1262.	1.1	14
34	PPARA: A Novel Genetic Determinant of CYP3A4 In Vitro and In Vivo. Clinical Pharmacology and Therapeutics, 2012, 91, 1044-1052.	4.7	131
35	Effect of CYP2B6*6 and CYP2C19*2 genotype on chlorpyrifos metabolism. Toxicology, 2012, 293, 115-122.	4.2	27
36	Paraoxonase (PON1 and PON3) Polymorphisms: Impact on Liver Expression and Atorvastatin-Lactone Hydrolysis. Frontiers in Pharmacology, 2011, 2, 41.	3.5	41

#	Article	IF	Citations
37	Transcriptional Profiling of Human Liver Identifies Sex-Biased Genes Associated with Polygenic Dyslipidemia and Coronary Artery Disease. PLoS ONE, 2011, 6, e23506.	2.5	143
38	Pathway-Targeted Pharmacogenomics of CYP1A2 in Human Liver. Frontiers in Pharmacology, 2010, 1, 129.	3.5	81
39	Profiling Induction of Cytochrome P450 Enzyme Activity by Statins Using a New Liquid Chromatography-Tandem Mass Spectrometry Cocktail Assay in Human Hepatocytes. Drug Metabolism and Disposition, 2010, 38, 1589-1597.	3.3	81
40	A Predominate Role of CYP1A2 for the Metabolism of Nabumetone to the Active Metabolite, 6-Methoxy-2-naphthylacetic Acid, in Human Liver Microsomes. Drug Metabolism and Disposition, 2009, 37, 1017-1024.	3.3	42
41	Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics, 2009, 10, 579-599.	1.3	125
42	Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology, 2009, 50, 1227-1240.	7.3	316
43	RNA-Interference Approach to Study Functions of NADPHÃ¢Â€Â‰:Ã¢Â€Â‰Cytochrome P450 Oxidoreductase in Human Hepatocytes. Chemistry and Biodiversity, 2009, 6, 2084-2091.	2.1	9
44	Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and Bioanalytical Chemistry, 2008, 392, 1093-1108.	3.7	510
45	Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene. Cancer Chemotherapy and Pharmacology, 2008, 61, 481-488.	2.3	24
46	Non-synonymous polymorphisms in the human SLCO1B1 gene: an in vitro analysis of SNPÂc.1929A>C. Molecular Genetics and Genomics, 2008, 279, 149-157.	2.1	9
47	Role of Genetic and Nongenetic Factors for Fluorouracil Treatment-Related Severe Toxicity: A Prospective Clinical Trial by the German 5-FU Toxicity Study Group. Journal of Clinical Oncology, 2008, 26, 2131-2138.	1.6	360
48	Aberrant Splicing Caused by Single Nucleotide Polymorphism c.516G>T [Q172H], a Marker of CYP2B6*6, Is Responsible for Decreased Expression and Activity of CYP2B6 in Liver. Journal of Pharmacology and Experimental Therapeutics, 2008, 325, 284-292.	2.5	201
49	Carbonyl Reductase 1 Is a Predominant Doxorubicin Reductase in the Human Liver. Drug Metabolism and Disposition, 2008, 36, 2113-2120.	3.3	158
50	Molecular Mechanism of Basal CYP3A4 Regulation by Hepatocyte Nuclear Factor 4Î±: Evidence for Direct Regulation in the Intestine. Drug Metabolism and Disposition, 2007, 35, 946-954.	3.3	43
51	A Natural Variant of the Heme-Binding Signature (R441C) Resulting in Complete Loss of Function of CYP2D6. Drug Metabolism and Disposition, 2007, 35, 1247-1250.	3.3	22
52	Sex-dependent genetic markers of CYP3A4 expression and activity in human liver microsomes. Pharmacogenomics, 2007, 8, 443-453.	1.3	63
53	Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism inÂvitro. Pharmacogenomics, 2007, 8, 547-558.	1.3	196
54	Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics, 2007, 8, 743-759.	1.3	252

#	Article	IF	Citations
55	MALDI-TOF Mass Spectrometry for Multiplex Genotyping of CYP2B6 Single-Nucleotide Polymorphisms. Clinical Chemistry, 2007, 53, 24-33.	3.2	37
56	Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations. Pharmacogenetics and Genomics, 2006, 16, 59-71.	1.5	38
57	Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events. Pharmacogenetics and Genomics, 2006, 16, 755-766.	1.5	80
58	A silent mutation (2939G>A, exon 6; CYP2D6*59) leading to impaired expression and function of CYP2D6. Pharmacogenetics and Genomics, 2006, 16, 767-770.	1.5	18
59	Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clinical Pharmacology and Therapeutics, 2006, 80, 440-456.e7.	4.7	113
60	Three haplotypes associated with CYP2A6 phenotypes in Caucasians. Pharmacogenetics and Genomics, 2005, 15, 609-624.	1.5	86
61	Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with efavirenz. Pharmacogenetics and Genomics, 2005, 15, 861-873.	1.5	232
62	Impact of Genetic Polymorphism in Relation to Other Factors on Expression and Function of Human Drug-Metabolizing P450s. Toxicology Mechanisms and Methods, 2005, 15, 121-124.	2.7	17
63	A Natural CYP2B6 TATA Box Polymorphism (â€“82Tâ†' C) Leading to Enhanced Transcription and Relocation of the Transcriptional Start Site. Molecular Pharmacology, 2005, 67, 1772-1782.	2.3	106
64	Multiple Novel Nonsynonymous CYP2B6 Gene Polymorphisms in Caucasians: Demonstration of Phenotypic Null Alleles. Journal of Pharmacology and Experimental Therapeutics, 2004, 311, 34-43.	2.5	128
65	A novel intronic mutation, 2988G>A, with high predictivity for impaired function of cytochrome P450 2D6 in white subjects*1. Clinical Pharmacology and Therapeutics, 2004, 76, 128-138.	4.7	160
66	Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver. Pharmacogenetics and Genomics, 2004, 14, 155-164.	5.7	113
67	Sex is a major determinant of CYP3A4 expression in human liver. Hepatology, 2003, 38, 978-988.	7.3	426
68	Large interindividual variability in the in vitro formation of tamoxifen metabolites related to the development of genotoxicity. British Journal of Clinical Pharmacology, 2003, 57, 105-111.	2.4	21
69	Influence of Omeprazole on Multidrug Resistance Protein 3 Expression in Human Liver. Journal of Pharmacology and Experimental Therapeutics, 2003, 304, 524-530.	2.5	46
70	Sex is a major determinant of CYP3A4 expression in human liver. Hepatology, 2003, 38, 978-988.	7.3	244
71	Detection of single nucleotide polymorphisms in CYP2B6 gene. Methods in Enzymology, 2002, 357, 45-53.	1.0	9
72	Molecular Mechanisms of Polymorphic CYP3A7 Expression in Adult Human Liver and Intestine. Journal of Biological Chemistry, 2002, 277, 24280-24288.	3.4	164

#	Article	IF	Citations
73	Re: Modification of Clinical Presentation of Prostate Tumors by a Novel Genetic Variant in CYP3A4. Journal of the National Cancer Institute, 2002, 94, 630-630.	6.3	43
74	A Naturally Occurring Mutation in the SLC21A6Gene Causing Impaired Membrane Localization of the Hepatocyte Uptake Transporter. Journal of Biological Chemistry, 2002, 277, 43058-43063.	3.4	127
75	Discriminative Quantification of Cytochrome P4502D6 and 2D7/8 Pseudogene Expression by TaqMan Real-Time Reverse Transcriptase Polymerase Chain Reaction. Analytical Biochemistry, 2002, 300, 121-131.	2.4	22
76	The influence ofCYP2B6,CYP2C9andCYP2D6genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. British Journal of Clinical Pharmacology, 2002, 54, 157-167.	2.4	118
77	Genetic polymorphisms of glutathione S-transferase A1, the major glutathione S-transferase in human liver: Consequences for enzyme expression and busulfan conjugation*. Clinical Pharmacology and Therapeutics, 2002, 71, 479-487.	4.7	73
78	Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics and Genomics, 2001, 11, 399-415.	5.7	556
79	The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics and Genomics, 2001, 11, 773-779.	5.7	608